A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.
Latest Information Update: 14 May 2024
At a glance
- Drugs SGM 101 (Primary)
- Indications Brain metastases; Colorectal cancer
- Focus Diagnostic use
- Acronyms SGM-CBM
- 07 May 2024 Planned End Date changed from 1 Dec 2024 to 1 Feb 2026.
- 07 May 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Feb 2026.
- 17 Nov 2023 New source identified and integrated European Clinical Trials Database (EudraCT2020-003804-15)